Hosted on MSN5h
Two drugs prove to be effective against Alzheimer's disease in new study
A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10–13 ...
FiercePharma17h
Eisai to part ways with 121 employees amid new US restructuring effort
Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
Seizures Pipeline Insight Analysis Report, Competitive Analysis of Eisai, Novartis, Johnson & Johnson, and Neurelis
The "Seizures Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The Seizures treatment pipeline analysis provides an overview of recent advancements ...
Eisai: Will Have No Problem Hitting Leqembi Forecasts
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...